Do analysts recommend ADXS or SPRB?

Spruce Biosciences has a consensus target price of $169.67, suggesting a potential upside of 246.05%. Given Spruce Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Spruce Biosciences is more favorable than Ayala Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ayala Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Spruce Biosciences 1 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.56

Is ADXS or SPRB more profitable?

Ayala Pharmaceuticals' return on equity of 0.00% beat Spruce Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Ayala Pharmaceuticals N/A N/A N/A Spruce Biosciences N/A -155.40% -101.67%

Does the media refer more to ADXS or SPRB?

In the previous week, Spruce Biosciences had 7 more articles in the media than Ayala Pharmaceuticals. MarketBeat recorded 8 mentions for Spruce Biosciences and 1 mentions for Ayala Pharmaceuticals. Spruce Biosciences' average media sentiment score of 1.12 beat Ayala Pharmaceuticals' score of 0.00 indicating that Spruce Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ayala Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Spruce Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate ADXS or HURA?

TuHURA Biosciences has a consensus price target of $9.00, suggesting a potential upside of 345.54%. Given TuHURA Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe TuHURA Biosciences is more favorable than Ayala Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ayala Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 TuHURA Biosciences 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.67

Is ADXS or HURA more profitable?

Ayala Pharmaceuticals' return on equity of 0.00% beat TuHURA Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Ayala Pharmaceuticals N/A N/A N/A TuHURA Biosciences N/A -156.12% -105.38%

Does the media favor ADXS or HURA?

In the previous week, TuHURA Biosciences had 1 more articles in the media than Ayala Pharmaceuticals. MarketBeat recorded 2 mentions for TuHURA Biosciences and 1 mentions for Ayala Pharmaceuticals. TuHURA Biosciences' average media sentiment score of 0.93 beat Ayala Pharmaceuticals' score of 0.00 indicating that TuHURA Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ayala Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral TuHURA Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate ADXS or GNLX?

Genelux has a consensus price target of $18.00, indicating a potential upside of 504.03%. Given Genelux's stronger consensus rating and higher probable upside, analysts plainly believe Genelux is more favorable than Ayala Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ayala Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Genelux 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50

Is ADXS or GNLX more profitable?

Ayala Pharmaceuticals' return on equity of 0.00% beat Genelux's return on equity. Company Net Margins Return on Equity Return on Assets Ayala Pharmaceuticals N/A N/A N/A Genelux N/A -174.55% -123.65%

Does the media refer more to ADXS or GNLX?

In the previous week, Genelux had 2 more articles in the media than Ayala Pharmaceuticals. MarketBeat recorded 3 mentions for Genelux and 1 mentions for Ayala Pharmaceuticals. Genelux's average media sentiment score of 0.43 beat Ayala Pharmaceuticals' score of 0.00 indicating that Genelux is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ayala Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Genelux 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer CGTX or ADXS?

Cognition Therapeutics presently has a consensus target price of $3.33, indicating a potential upside of 189.86%. Given Cognition Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Cognition Therapeutics is more favorable than Ayala Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cognition Therapeutics 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 Ayala Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is CGTX or ADXS more profitable?

Ayala Pharmaceuticals' return on equity of 0.00% beat Cognition Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Cognition Therapeutics N/A -72.68% -53.07% Ayala Pharmaceuticals N/A N/A N/A

Does the media prefer CGTX or ADXS?

In the previous week, Cognition Therapeutics had 2 more articles in the media than Ayala Pharmaceuticals. MarketBeat recorded 3 mentions for Cognition Therapeutics and 1 mentions for Ayala Pharmaceuticals. Cognition Therapeutics' average media sentiment score of 0.83 beat Ayala Pharmaceuticals' score of 0.00 indicating that Cognition Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cognition Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ayala Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer ACOG or ADXS?

Alpha Cognition currently has a consensus price target of $14.67, indicating a potential upside of 144.44%. Given Alpha Cognition's stronger consensus rating and higher possible upside, equities analysts plainly believe Alpha Cognition is more favorable than Ayala Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alpha Cognition 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Ayala Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Does the media prefer ACOG or ADXS?

In the previous week, Alpha Cognition had 1 more articles in the media than Ayala Pharmaceuticals. MarketBeat recorded 2 mentions for Alpha Cognition and 1 mentions for Ayala Pharmaceuticals. Alpha Cognition's average media sentiment score of 1.89 beat Ayala Pharmaceuticals' score of 0.00 indicating that Alpha Cognition is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alpha Cognition 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Ayala Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Ayala Pharmaceuticals (ADXS) Competitors

$0.60 0.00 (0.00%)

As of 06/8/2026

Compare

ADXS vs. SPRB, HURA, GNLX, CGTX, and ACOG

Should you buy Ayala Pharmaceuticals stock or one of its competitors? MarketBeat compares Ayala Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Ayala Pharmaceuticals include Spruce Biosciences (SPRB), TuHURA Biosciences (HURA), Genelux (GNLX), Cognition Therapeutics (CGTX), and Alpha Cognition (ACOG). These companies are all part of the "pharmaceutical products" industry.

How does Ayala Pharmaceuticals compare to Spruce Biosciences?

Ayala Pharmaceuticals (NASDAQ:ADXS) and Spruce Biosciences (NASDAQ:SPRB) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, analyst recommendations, media sentiment, dividends and earnings.

In the previous week, Spruce Biosciences had 7 more articles in the media than Ayala Pharmaceuticals. MarketBeat recorded 8 mentions for Spruce Biosciences and 1 mentions for Ayala Pharmaceuticals. Spruce Biosciences' average media sentiment score of 1.12 beat Ayala Pharmaceuticals' score of 0.00 indicating that Spruce Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ayala Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Spruce Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Ayala Pharmaceuticals' return on equity of 0.00% beat Spruce Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ayala Pharmaceuticals	N/A	N/A	N/A
Spruce Biosciences	N/A	-155.40%	-101.67%

Ayala Pharmaceuticals has a beta of 1.75, meaning that its stock price is 75% more volatile than the broader market. Comparatively, Spruce Biosciences has a beta of 3.11, meaning that its stock price is 211% more volatile than the broader market.

Spruce Biosciences has a consensus target price of $169.67, suggesting a potential upside of 246.05%. Given Spruce Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Spruce Biosciences is more favorable than Ayala Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ayala Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Spruce Biosciences	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56

7.2% of Ayala Pharmaceuticals shares are held by institutional investors. Comparatively, 91.7% of Spruce Biosciences shares are held by institutional investors. 0.6% of Ayala Pharmaceuticals shares are held by insiders. Comparatively, 4.3% of Spruce Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Spruce Biosciences has higher revenue and earnings than Ayala Pharmaceuticals. Spruce Biosciences is trading at a lower price-to-earnings ratio than Ayala Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ayala Pharmaceuticals	$3.24M	11.05	-$48.07M	-$5.02	N/A
Spruce Biosciences	$4.91M	27.46	-$38.97M	-$36.60	N/A

Summary

Spruce Biosciences beats Ayala Pharmaceuticals on 11 of the 15 factors compared between the two stocks.

How does Ayala Pharmaceuticals compare to TuHURA Biosciences?

Ayala Pharmaceuticals (NASDAQ:ADXS) and TuHURA Biosciences (NASDAQ:HURA) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, profitability, valuation, media sentiment, dividends and risk.

In the previous week, TuHURA Biosciences had 1 more articles in the media than Ayala Pharmaceuticals. MarketBeat recorded 2 mentions for TuHURA Biosciences and 1 mentions for Ayala Pharmaceuticals. TuHURA Biosciences' average media sentiment score of 0.93 beat Ayala Pharmaceuticals' score of 0.00 indicating that TuHURA Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ayala Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
TuHURA Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Ayala Pharmaceuticals' return on equity of 0.00% beat TuHURA Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ayala Pharmaceuticals	N/A	N/A	N/A
TuHURA Biosciences	N/A	-156.12%	-105.38%

TuHURA Biosciences has lower revenue, but higher earnings than Ayala Pharmaceuticals. TuHURA Biosciences is trading at a lower price-to-earnings ratio than Ayala Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ayala Pharmaceuticals	$3.24M	11.05	-$48.07M	-$5.02	N/A
TuHURA Biosciences	N/A	N/A	-$30.05M	-$0.61	N/A

7.2% of Ayala Pharmaceuticals shares are owned by institutional investors. Comparatively, 0.6% of TuHURA Biosciences shares are owned by institutional investors. 0.6% of Ayala Pharmaceuticals shares are owned by insiders. Comparatively, 0.2% of TuHURA Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

TuHURA Biosciences has a consensus price target of $9.00, suggesting a potential upside of 345.54%. Given TuHURA Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe TuHURA Biosciences is more favorable than Ayala Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ayala Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
TuHURA Biosciences	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Ayala Pharmaceuticals has a beta of 1.75, meaning that its share price is 75% more volatile than the broader market. Comparatively, TuHURA Biosciences has a beta of 0.01, meaning that its share price is 99% less volatile than the broader market.

Summary

Ayala Pharmaceuticals and TuHURA Biosciences tied by winning 7 of the 14 factors compared between the two stocks.

How does Ayala Pharmaceuticals compare to Genelux?

Ayala Pharmaceuticals (NASDAQ:ADXS) and Genelux (NASDAQ:GNLX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, earnings, risk, valuation, analyst recommendations, profitability, institutional ownership and media sentiment.

Genelux has lower revenue, but higher earnings than Ayala Pharmaceuticals. Genelux is trading at a lower price-to-earnings ratio than Ayala Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ayala Pharmaceuticals	$3.24M	11.05	-$48.07M	-$5.02	N/A
Genelux	$10K	13,362.32	-$32.15M	-$0.85	N/A

Ayala Pharmaceuticals has a beta of 1.75, indicating that its stock price is 75% more volatile than the broader market. Comparatively, Genelux has a beta of 0.56, indicating that its stock price is 44% less volatile than the broader market.

7.2% of Ayala Pharmaceuticals shares are owned by institutional investors. Comparatively, 37.3% of Genelux shares are owned by institutional investors. 0.6% of Ayala Pharmaceuticals shares are owned by insiders. Comparatively, 7.5% of Genelux shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Genelux has a consensus price target of $18.00, indicating a potential upside of 504.03%. Given Genelux's stronger consensus rating and higher probable upside, analysts plainly believe Genelux is more favorable than Ayala Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ayala Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Genelux	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Genelux had 2 more articles in the media than Ayala Pharmaceuticals. MarketBeat recorded 3 mentions for Genelux and 1 mentions for Ayala Pharmaceuticals. Genelux's average media sentiment score of 0.43 beat Ayala Pharmaceuticals' score of 0.00 indicating that Genelux is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ayala Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Genelux	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Ayala Pharmaceuticals' return on equity of 0.00% beat Genelux's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ayala Pharmaceuticals	N/A	N/A	N/A
Genelux	N/A	-174.55%	-123.65%

Summary

Genelux beats Ayala Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

How does Ayala Pharmaceuticals compare to Cognition Therapeutics?

Cognition Therapeutics (NASDAQ:CGTX) and Ayala Pharmaceuticals (NASDAQ:ADXS) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, media sentiment, earnings, risk and analyst recommendations.

Ayala Pharmaceuticals' return on equity of 0.00% beat Cognition Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cognition Therapeutics	N/A	-72.68%	-53.07%
Ayala Pharmaceuticals	N/A	N/A	N/A

Cognition Therapeutics has a beta of 1.75, meaning that its stock price is 75% more volatile than the broader market. Comparatively, Ayala Pharmaceuticals has a beta of 1.75, meaning that its stock price is 75% more volatile than the broader market.

43.4% of Cognition Therapeutics shares are owned by institutional investors. Comparatively, 7.2% of Ayala Pharmaceuticals shares are owned by institutional investors. 11.1% of Cognition Therapeutics shares are owned by insiders. Comparatively, 0.6% of Ayala Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Cognition Therapeutics presently has a consensus target price of $3.33, indicating a potential upside of 189.86%. Given Cognition Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Cognition Therapeutics is more favorable than Ayala Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cognition Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Ayala Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Cognition Therapeutics has higher earnings, but lower revenue than Ayala Pharmaceuticals. Cognition Therapeutics is trading at a lower price-to-earnings ratio than Ayala Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cognition Therapeutics	N/A	N/A	-$23.49M	-$0.24	N/A
Ayala Pharmaceuticals	$3.24M	11.05	-$48.07M	-$5.02	N/A

In the previous week, Cognition Therapeutics had 2 more articles in the media than Ayala Pharmaceuticals. MarketBeat recorded 3 mentions for Cognition Therapeutics and 1 mentions for Ayala Pharmaceuticals. Cognition Therapeutics' average media sentiment score of 0.83 beat Ayala Pharmaceuticals' score of 0.00 indicating that Cognition Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cognition Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ayala Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Cognition Therapeutics beats Ayala Pharmaceuticals on 9 of the 13 factors compared between the two stocks.

How does Ayala Pharmaceuticals compare to Alpha Cognition?

Alpha Cognition (NASDAQ:ACOG) and Ayala Pharmaceuticals (NASDAQ:ADXS) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, valuation, institutional ownership, risk, dividends, earnings and analyst recommendations.

Alpha Cognition has a beta of 2.36, meaning that its share price is 136% more volatile than the broader market. Comparatively, Ayala Pharmaceuticals has a beta of 1.75, meaning that its share price is 75% more volatile than the broader market.

Alpha Cognition currently has a consensus price target of $14.67, indicating a potential upside of 144.44%. Given Alpha Cognition's stronger consensus rating and higher possible upside, equities analysts plainly believe Alpha Cognition is more favorable than Ayala Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alpha Cognition	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Ayala Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

7.2% of Ayala Pharmaceuticals shares are held by institutional investors. 14.0% of Alpha Cognition shares are held by company insiders. Comparatively, 0.6% of Ayala Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Alpha Cognition had 1 more articles in the media than Ayala Pharmaceuticals. MarketBeat recorded 2 mentions for Alpha Cognition and 1 mentions for Ayala Pharmaceuticals. Alpha Cognition's average media sentiment score of 1.89 beat Ayala Pharmaceuticals' score of 0.00 indicating that Alpha Cognition is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alpha Cognition	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Ayala Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Alpha Cognition has higher revenue and earnings than Ayala Pharmaceuticals. Alpha Cognition is trading at a lower price-to-earnings ratio than Ayala Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alpha Cognition	$10.22M	12.78	-$20.67M	-$1.35	N/A
Ayala Pharmaceuticals	$3.24M	11.05	-$48.07M	-$5.02	N/A

Ayala Pharmaceuticals has a net margin of 0.00% compared to Alpha Cognition's net margin of -232.23%. Ayala Pharmaceuticals' return on equity of 0.00% beat Alpha Cognition's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alpha Cognition	-232.23%	-58.35%	-45.99%
Ayala Pharmaceuticals	N/A	N/A	N/A

Summary

Alpha Cognition beats Ayala Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

Get Ayala Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ADXS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ADXS vs. The Competition

Export

Metric	Ayala Pharmaceuticals	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$35.79M	$958.36M	$6.65B	$12.06B
Dividend Yield	N/A	4.84%	2.67%	5.55%
P/E Ratio	-0.08	1.46	24.73	23.76
Price / Sales	11.05	127.56	507.94	105.22
Price / Cash	N/A	20.06	42.36	56.09
Price / Book	-0.29	7.90	10.36	6.72
Net Income	-$48.07M	-$4.82M	$3.56B	$337.35M
7 Day Performance	N/A	-1.57%	-0.96%	-1.21%
1 Month Performance	N/A	3.80%	1.26%	1.41%
1 Year Performance	N/A	96.26%	20.46%	23.64%

Ayala Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ADXS Ayala Pharmaceuticals	N/A	$0.60 flat	N/A	N/A	$35.79M	$3.24M	N/A	20
SPRB Spruce Biosciences	3.0149 of 5 stars	$49.75 +1.4%	$176.60 +254.9%	+989.6%	$136.68M	$4.91M	N/A	20	Positive News Analyst Forecast Gap Up
HURA TuHURA Biosciences	2.1086 of 5 stars	$2.18 +2.6%	$9.00 +313.8%	-29.9%	$136.21M	N/A	N/A	N/A
GNLX Genelux	2.0268 of 5 stars	$3.01 +0.3%	$18.00 +498.0%	+10.0%	$135.82M	$10K	N/A	10	Gap Up
CGTX Cognition Therapeutics	3.983 of 5 stars	$1.43 +1.0%	$3.33 +132.5%	+280.4%	$133.80M	N/A	N/A	20	Positive News Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ADXS) was last updated on 6/10/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Ayala Pharmaceuticals (ADXS) Competitors

ADXS vs. SPRB, HURA, GNLX, CGTX, and ACOG

How does Ayala Pharmaceuticals compare to Spruce Biosciences?

Summary

How does Ayala Pharmaceuticals compare to TuHURA Biosciences?

Summary

How does Ayala Pharmaceuticals compare to Genelux?

Summary

How does Ayala Pharmaceuticals compare to Cognition Therapeutics?

Summary

How does Ayala Pharmaceuticals compare to Alpha Cognition?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADXS vs. The Competition

Ayala Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Ayala Pharmaceuticals (ADXS) Competitors

ADXS vs. SPRB, HURA, GNLX, CGTX, and ACOG

How does Ayala Pharmaceuticals compare to Spruce Biosciences?

Does the media refer more to ADXS or SPRB?

Is ADXS or SPRB more profitable?

Which has more risk and volatility, ADXS or SPRB?

Do analysts recommend ADXS or SPRB?

Do insiders and institutionals have more ownership in ADXS or SPRB?

Which has preferable valuation & earnings, ADXS or SPRB?

Summary

How does Ayala Pharmaceuticals compare to TuHURA Biosciences?

Does the media favor ADXS or HURA?

Is ADXS or HURA more profitable?

Which has preferable earnings & valuation, ADXS or HURA?

Do insiders & institutionals have more ownership in ADXS or HURA?

Do analysts rate ADXS or HURA?

Which has more volatility & risk, ADXS or HURA?

Summary

How does Ayala Pharmaceuticals compare to Genelux?

Which has better valuation and earnings, ADXS or GNLX?

Which has more volatility and risk, ADXS or GNLX?

Do insiders and institutionals hold more shares of ADXS or GNLX?

Do analysts rate ADXS or GNLX?

Does the media refer more to ADXS or GNLX?

Is ADXS or GNLX more profitable?

Summary

How does Ayala Pharmaceuticals compare to Cognition Therapeutics?

Is CGTX or ADXS more profitable?

Which has more volatility and risk, CGTX or ADXS?

Do institutionals & insiders believe in CGTX or ADXS?

Do analysts prefer CGTX or ADXS?

Which has preferable valuation and earnings, CGTX or ADXS?

Does the media prefer CGTX or ADXS?

Summary

How does Ayala Pharmaceuticals compare to Alpha Cognition?

Which has more risk & volatility, ACOG or ADXS?

Do analysts prefer ACOG or ADXS?

Do institutionals and insiders believe in ACOG or ADXS?

Does the media prefer ACOG or ADXS?

Which has stronger earnings & valuation, ACOG or ADXS?

Is ACOG or ADXS more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADXS vs. The Competition

Ayala Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools